Dec. 17, 2025 — Kirin Holdings Company, Limited and Fujitsu Limited have jointly conducted research on food functionality simulation with the goal of creating new functionalities in food. This research utilized QSP (Quantitative Systems Pharmacology) models, one of the AI-driven digital transformation (DX) technologies for drug discovery, combined with real-world experimental validation.
Simulation-based evaluation of ligand-binding cholinergic receptors in enteric neurons using a QSP model (Credit: Fujitsu)
As a result, the study has, for the first time worldwide, identified a previously unknown mechanism within the gut-brain axis associated with citicoline, a compound known for its role in supporting cognitive health. This finding was obtained by combining virtual subject simulations based on advanced QSP technologies developed by Fujitsu in collaboration with its partner Nova In Silico SAS(France) with cell-based experimental validation.
Conventional drug discovery has been time-consuming and costly, with limitations in improving confidence in demonstrating efficacy in humans. In recent years, the diversification of medical needs and stricter constraints on animal testing have further increased the demand for efficient R&D. To address these challenges, the introduction of DX technologies utilizing AI and data science has been accelerating. In particular, virtual subject generation and in silico simulation enabled by DX technologies are expected to improve reliability in demonstrating efficacy in humans without animal testing, making their application in food functionality research highly promising.
This study represents a globally pioneering example of the full-scale application of DX technologies in food functionality research. It evaluated novel physiological functions of citicoline by combining AI-based prediction with experimental validation. These findings are expected to accelerate the adoption of AI-driven DX technologies in health science and contribute significantly to realizing a society that promotes longevity and well-being through innovative food solutions.
Research Results
Fujitsu collected information on citicoline’s metabolic profile and its action-related receptors from Kirin’s proprietary data and literature reviews. Using digital transformation (DX) technology, Fujitsu constructed a QSP model to evaluate the functional properties of citicoline. Simulations using this model predicted that oral administration of citicoline enhances cholinergic signaling in the gut–nerve axis and induces a dose-dependent increase in acetylcholine levels within intestinal synapses. In parallel, in vitro experimental validation confirmed that citicoline activates neuronal signaling through the intestinal pathway in a co-culture system of intestinal epithelial cells and neurons.
Key Findings
This study predicted, through AI-based analysis, that citicoline could activate neuronal signaling via the gut and validated this prediction in vitro. Furthermore, gut nerves are known to be closely interconnected with the brain. This research has elucidated part of the gut-brain mechanism of citicoline.
Future Plans
This study represents a globally pioneering example of the full-scale application of DX technology in food functionality research. It provides insights that help elucidate new physiological functions of citicoline, which are essential for supporting brain function, thereby enhancing citicoline’s value as a functional ingredient for health.
About Kirin Holdings
Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe. Kirin Holdings can trace its roots to Japan Brewery, which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company has expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.
About Fujitsu
Fujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share.
Source: Fujitsu
The post Fujitsu Applies AI-Based QSP Models to Identify Gut-Brain Mechanism Linked to Citicoline appeared first on AIwire.
